Press center

| Investor News

M1 Kliniken AG announces that the sale of HAEMATO Pharm GmbH by its majority holding, HAEMATO AG (85%), to the PHOENIX group was successfully completed effective as of the end of January 31, 2026.

| Investor News

The Supervisory Board of M1 Kliniken AG has appointed Ms. Katharina Zimmnau to the Executive Board of M1 Kliniken AG with effect from 10. December 2025.

| Investor News

  • Group revenue: +6.7% to EUR 274.3 million (YTD Q3 2024: EUR 257.2 million)
  • EBITDA: +9% to EUR 28.2 million (YTD Q3 2024: EUR 25.9 million)
  • EBIT: +11% to EUR 24.5 million (YTD Q3 2024: EUR 22.1 million)
  • EBIT margin: 8.9% (YTD Q3 2024: 8.6%)
  • EBT: +10% to EUR 24.4 million (YTD Q3 2024: EUR 22.2 million)
  • Earnings per share: EUR 0.86 (YTD Q3 2024: EUR 0.77)

Press contact

Press contact

Grünauer Straße 5
12557 Berlin
Germany

T. +49 (0) 30 347 47 44 14